<div id="readability-page-1"><p>In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Evolus, with a price target of <span id="expert-recommendation-target">$19.00</span>.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>According to TipRanks, Ear is a 2-star analyst with an average return of <span>1.2%</span> and a 39.09% success rate. Ear covers the Healthcare sector, focusing on stocks such as Tectonic Therapeutic, Arcutis Biotherapeutics, and Sarepta Therapeutics.</p> <p>In addition to Mizuho Securities, Evolus also received a Buy from H.C. Wainwright’s Douglas Tsao in a report issued on December 2. However, on December 7, TR | OpenAI – 4o reiterated a Hold rating on Evolus (NASDAQ: EOLS).</p></div>

EOLS

<p>Mizuho Securities' Uy Ear maintained a Buy rating on Evolus (EOLS) with a price target of $19.00. Ear is a 2-star analyst with a 1.2% average return and a 39.09% success rate. Evolus also received a Buy rating from H.C. Wainwright's Douglas Tsao on December 2, while TR reiterated a Hold rating on December 7.</p>

Mizuho Securities Keeps Their Buy Rating on Evolus (EOLS)